Synonym
ALC-0315; ALC 0315; ALC0315;
IUPAC/Chemical Name
[(4-Hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate)
InChi Key
QGWBEETXHOVFQS-UHFFFAOYSA-N
InChi Code
InChI=1S/C48H95NO5/c1-5-9-13-17-19-27-37-45(35-25-15-11-7-3)47(51)53-43-33-23-21-29-39-49(41-31-32-42-50)40-30-22-24-34-44-54-48(52)46(36-26-16-12-8-4)38-28-20-18-14-10-6-2/h45-46,50H,5-44H2,1-4H3
SMILES Code
OCCCCN(CCCCCCOC(C(CCCCCC)CCCCCCCC)=O)CCCCCCOC(C(CCCCCC)CCCCCCCC)=O
Appearance
Colorless to light yellow oily liquid
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Chloroform (50mg/mL) and ethanol (100mg/mL)
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
ALC-0315 is a synthetic cationic lipid (or ionizable lipid).
|
Solvent |
mg/mL |
mM |
| Solubility |
| chloroform |
50.0 |
65.25 |
| ethanol |
100.0 |
130.51 |
| DMSO |
50.0 |
65.25 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
766.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells. Mol Pharm. 2022 Jul 4;19(7):2175-2182. doi: 10.1021/acs.molpharmaceut.2c00033. Epub 2022 May 31. PMID: 35642083; PMCID: PMC9621687.
2: Chen J, Ye Z, Huang C, Qiu M, Song D, Li Y, Xu Q. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2207841119. doi: 10.1073/pnas.2207841119. Epub 2022 Aug 15. PMID: 35969778; PMCID: PMC9407666.
3: Saadati F, Cammarone S, Ciufolini MA. A Route to Lipid ALC-0315: a Key Component of a COVID-19 mRNA Vaccine. Chemistry. 2022 Aug 26;28(48):e202200906. doi: 10.1002/chem.202200906. Epub 2022 Jul 4. PMID: 35665545; PMCID: PMC9348069.
4: Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021 Mar 3;29(3):898-900. doi: 10.1016/j.ymthe.2021.01.030. Epub 2021 Feb 5. PMID: 33571463; PMCID: PMC7862013.
5: Morais P, Adachi H, Yu YT. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Front Cell Dev Biol. 2021 Nov 4;9:789427. doi: 10.3389/fcell.2021.789427. PMID: 34805188; PMCID: PMC8600071.
6: Ly HH, Daniel S, Soriano SKV, Kis Z, Blakney AK. Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of- Experiment Approach. Mol Pharm. 2022 Jun 6;19(6):1892-1905. doi: 10.1021/acs.molpharmaceut.2c00032. Epub 2022 May 23. PMID: 35604765; PMCID: PMC9176215.
7: Boldyrev IA, Shendrikov VP, Vostrova AG, Vodovozova EL. A Route to Synthesize Ionizable Lipid ALC-0315, a Key Component of the mRNA Vaccine Lipid Matrix. Russ J Bioorg Chem. 2023;49(2):412-415. doi: 10.1134/S1068162023020061. Epub 2023 May 19. PMID: 37252003; PMCID: PMC10197038.
8: Trollmann MFW, Böckmann RA. mRNA lipid nanoparticle phase transition. Biophys J. 2022 Oct 18;121(20):3927-3939. doi: 10.1016/j.bpj.2022.08.037. Epub 2022 Aug 31. PMID: 36045573; PMCID: PMC9674992.
9: Ermilova I, Swenson J. Ionizable lipids penetrate phospholipid bilayers with high phase transition temperatures: perspectives from free energy calculations. Chem Phys Lipids. 2023 Jul;253:105294. doi: 10.1016/j.chemphyslip.2023.105294. Epub 2023 Mar 31. PMID: 37003484.
10: Qin S, Huang H, Xiao W, Chen K, He X, Tang X, Huang Z, Zhang Y, Duan X, Fan N, Zheng Q, Wu M, Lu G, Wei Y, Wei X, Song X. A novel heterologous receptor- binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. Acta Pharm Sin B. 2023 Jan 12. doi: 10.1016/j.apsb.2023.01.010. Epub ahead of print. PMID: 36647424; PMCID: PMC9833852.
11: Lam K, Leung A, Martin A, Wood M, Schreiner P, Palmer L, Daly O, Zhao W, McClintock K, Heyes J. Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid-Nanoparticle Components for Therapeutic and Vaccine Applications. Adv Mater. 2023 Apr;35(15):e2209624. doi: 10.1002/adma.202209624. Epub 2023 Mar 5. PMID: 36680477.
12: Radice A, Fassio F, Meucci E, Iorno MCL, Macchia D. Potential culprits for immediate hypersensitivity reactions to BNT162b2 mRNA COVID-19 vaccine: not just PEG. Eur Ann Allergy Clin Immunol. 2021 Sep;53(5):240-242. doi: 10.23822/EurAnnACI.1764-1489.214. Epub 2021 Apr 29. PMID: 33913314.
13: Du S, Li W, Zhang Y, Xue Y, Hou X, Yan J, Cheng J, Deng B, McComb DW, Lin J, Zeng H, Cheng X, Irvine DJ, Weiss R, Dong Y. Cholesterol-Amino-Phosphate (CAP) Derived Lipid Nanoparticles for Delivery of Self-Amplifying RNA and Restoration of Spermatogenesis in Infertile Mice. Adv Sci (Weinh). 2023 Apr;10(11):e2300188. doi: 10.1002/advs.202300188. Epub 2023 Feb 7. PMID: 36748274; PMCID: PMC10104632.
14: Yu SY, Carlaw T, Thomson T, Birkenshaw A, Basha G, Kurek D, Huang C, Kulkarni J, Zhang LH, Ross CJD. A luciferase reporter mouse model to optimize in vivo gene editing validated by lipid nanoparticle delivery of adenine base editors. Mol Ther. 2023 Apr 5;31(4):1159-1166. doi: 10.1016/j.ymthe.2023.02.009. Epub 2023 Feb 15. PMID: 36793209; PMCID: PMC10124072.
1. Xue Y, Zhang Y, Zhong Y, Du S, Hou X, Li W, Li H, Wang S, Wang C, Yan J, Kang DD, Deng B, McComb DW, Irvine DJ, Weiss R, Dong Y. LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing. Nat Commun. 2024 Jan 25;15(1):739. doi: 10.1038/s41467-024-45094-5. PMID: 38272900; PMCID: PMC10811230.
2. Zhang W, Pfeifle A, Lansdell C, Frahm G, Cecillon J, Tamming L, Gravel C, Gao J, Thulasi Raman SN, Wang L, Sauve S, Rosu-Myles M, Li X, Johnston MJW. The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice. Vaccines (Basel). 2023 Oct 11;11(10):1580. doi: 10.3390/vaccines11101580. PMID: 37896985; PMCID: PMC10610642.
3. Jalil S, Keskinen T, Juutila J, Sartori Maldonado R, Euro L, Suomalainen A, Lapatto R, Kuuluvainen E, Hietakangas V, Otonkoski T, Hyvönen ME, Wartiovaara K. Genetic and functional correction of argininosuccinate lyase deficiency using CRISPR adenine base editors. Am J Hum Genet. 2024 Apr 4;111(4):714-728. doi: 10.1016/j.ajhg.2024.03.004. PMID: 38579669; PMCID: PMC11023919.
4. S Jalil - helda.helsinki.fi. Advancing Genetic Therapies: Developing Precision CRISPR Editing for Rare.
5. Im SH, Chung Y, Duskunovic N, Choi H, Park SH, Chung HJ. Oligonucleotide-Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform. Adv Healthc Mater. 2024 Oct 3:e2401868. doi: 10.1002/adhm.202401868. Epub ahead of print. PMID: 39363681.
6. Fazel F, Matsuyama-Kato A, Alizadeh M, Zheng J, Fletcher C, Gupta B, St-Denis M, Boodhoo N, Sharif S. A Marek's Disease Virus Messenger RNA-Based Vaccine Modulates Local and Systemic Immune Responses in Chickens. Viruses. 2024 Jul 18;16(7):1156. doi: 10.3390/v16071156. PMID: 39066318; PMCID: PMC11281610.
7. Xue Y, Hou X, Zhong Y, Zhang Y, Du S, Kang DD, Wang L, Wang C, Li H, Wang S, Liu Z, Tian M, Guo K, Cao D, Deng B, McComb DW, Purisic E, Dai J, Hamon P, Brown BD, Tsankova NM, Merad M, Irvine DJ, Weiss R, Dong Y. LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment. Nat Commun. 2025 Mar 4;16(1):2198. doi: 10.1038/s41467-025-57149-2. PMID: 40038251; PMCID: PMC11880362.
